Ipsen S.A.
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
47.43%
Market Cap
8.78 Bil.
P/E Ratio
22.18
Dividend Yield
1.34 %
Earnings per Share
5.37 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 150.8 G | 0 Units |
| PRICE DETERMINATION TIME | 06/03/2026 / 09:55:40 PM | |
| DAILY VOLUME (UNITS) | 195 | |
| DAILY HIGH / LOW | 150.9 | 148.6 |
| PREV. DAY'S PRICE | 152 | (06/02) |
| CHANGE DAY BEFORE | -1.20 | -0.79 % |
| 52 WEEK HIGH / LOW | 173.2 (05/06) | 99.9 (06/23) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 13.15 | 13.39 | 5.37 | 4.18 | 7.79 |
| DIVIDENDS PER SHARE | 1.46 | 1.43 | 1.60 | 1.40 | 1.20 |
| DIVIDEND YIELD IN % | - | - | 1.34 % | 1.26 % | 1.11 % |
| DIVIDEND GROWTH IN % | - | - | 14.29 % | 16.67 % | 0.00 % |
| PRICE - EARNINGS RATIO | 11.91 | 11.69 | 22.18 | 26.49 | 13.85 |
| PRICE - BOOK RATIO | - | - | 2.27 | 2.19 | 2.33 |
| PRICE - SALES RATIO | - | - | 2.70 | 2.71 | 2.88 |
| PRICE - CASH FLOW RATIO | - | - | 8.72 | 10.17 | 10.67 |
Master Data
| WKN | A0ESMG |
| ISIN | FR0010259150 |
| SYMBOL | I7G |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Ipsen |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | 8.78 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -5.82 % | -8.87 % | -8.27 % | 23.18 % | 47.43 % | 37.18 % | 79.03 % | 28.70 % |
| HIGH | 161.50 | 173.20 | 173.20 | 173.20 | 173.20 | 173.20 | 173.20 | 173.20 |
| LOW | 150.50 | 150.50 | 145.20 | 115.70 | 99.90 | 87.95 | 77.32 | 115.70 |
Dividend
per share
Company profile
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.
Structured products for Ipsen S.A.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.